iNovacia Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 11


  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 1

iNovacia General Information


Provider of pre-clinical research services. The company is engaged in providing drug discovery services to the pharmaceutical companies for the discovery of new medicines.

Contact Information

Ownership Status
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Primary Office
  • Lindhagensgatan 133
  • 112 51 Stockholm
  • Sweden

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

iNovacia Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore iNovacia‘s full profile, request access.

Request a free trial

iNovacia Patents

iNovacia Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20080255153-A1 Pyrazolo[1,5- a ]-pyrimidine derivatives as human stearoyl-coa desaturase; cardiovascular, nervous system, autoimmune, metabolic and skin disorders; obesity, non-insulin-dependent diabetes; eczema, rosacea, acne, psoriasis; anticarcinogenic agents; modulation of plasma lipids Inactive 31-Aug-2007 0000000000
CA-2682016-A1 Pyrazolo [1,5-a]pyrimidines as inhibitors of stearoyl-coa desaturase Inactive 28-Mar-2007 0000000000
EP-2137187-A1 Pyrazolo [1,5-a]pyrimidines as inhibitors of stearoyl-coa desaturase Inactive 28-Mar-2007 0000000000
JP-2010522716-A Pyrazolo [1,5-a] pyrimidines as inhibitors of stearoyl-coa desaturase Inactive 28-Mar-2007 0000000000
US-20080103123-A1 4-phenyl-3-substituted pyridin compounds such as tert-butyl 4-[({5-[4-(methylsulfonyl)phenyl]pyridin-2-yl}oxy)methyl]-piperidine-1-carboxylate; agonists of the g-protein-coupled receptor gpr119; antidiabetic, antiinflammatory agent, neuropathy; use with a dipeptidyl peptidase iv (dpp iv) inhibitor Inactive 21-Nov-2006 A61K31/4545
To view iNovacia’s complete patent history, request access »

iNovacia Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial